Danila Madonna, Richard J Wakefield, Emilio Filippucci, Kulveer Mankia, Shouvik Dass, Dennis McGonagle, Paul Emery, Andrea Di Matteo
{"title":"Can Ultrasound Guide Treatment Decisions in Difficult-to-Treat Rheumatoid Arthritis?","authors":"Danila Madonna, Richard J Wakefield, Emilio Filippucci, Kulveer Mankia, Shouvik Dass, Dennis McGonagle, Paul Emery, Andrea Di Matteo","doi":"10.1002/art.70381","DOIUrl":"10.1002/art.70381","url":null,"abstract":"","PeriodicalId":129,"journal":{"name":"Arthritis & Rheumatology","volume":" ","pages":""},"PeriodicalIF":9.9,"publicationDate":"2026-10-20","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149226855","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Jaime Marty, Sara Martinez-Ramos, Carlos Rafael-Vidal, Beatriz Malvar-Fernández, Tiago Carvalheiro, Ralph G Tieland, Ines Ramos, Wiola Marut, Ana Pinheiro-Lopes, Ana Argibay, Brenda Maure, Caritina Vázquez-Triñanes, Nair Pérez Gómez, David Fernández-Fernández, Sandra Vila, Coral Mouriño, Rogier M Thurlings, Arjan van Caam, Alberto Rivera, José María Pego-Reigosa, Timothy R Radstake, Samuel Garcia
{"title":"Sema4A neutralization reduces fibrosis and inflammation in a mouse model of systemic sclerosis and a 3D model of immunity-driven fibrosis.","authors":"Jaime Marty, Sara Martinez-Ramos, Carlos Rafael-Vidal, Beatriz Malvar-Fernández, Tiago Carvalheiro, Ralph G Tieland, Ines Ramos, Wiola Marut, Ana Pinheiro-Lopes, Ana Argibay, Brenda Maure, Caritina Vázquez-Triñanes, Nair Pérez Gómez, David Fernández-Fernández, Sandra Vila, Coral Mouriño, Rogier M Thurlings, Arjan van Caam, Alberto Rivera, José María Pego-Reigosa, Timothy R Radstake, Samuel Garcia","doi":"10.1002/art.70374","DOIUrl":"https://doi.org/10.1002/art.70374","url":null,"abstract":"<p><p>OBJECTIVE: We previously showed that Semaphorin4A (Sema4A) is elevated in patients with systemic sclerosis (SSc) and promotes inflammation and fibrosis in vitro. Here, we examined the effect of Sema4A neutralization in vivo and in 3D fibrosis models.</p><p><strong>Methods: </strong>Sema4A plasma levels were measured by ELISA in healthy controls (n=31) and patients with SSc (n=30). In the bleomycin SSc-model, mice were treated with an anti-Sema4A neutralizing antibody or its respective isotype control (n=6-7). The 3D fibrosis models, consisting of collagen hydrogel, dermal fibroblasts, and peripheral blood mononuclear cells, were stimulated with recombinant Sema4A, rapamycin, or antibodies neutralizing Sema4A, PlexinD1, PlexinB2, Neuropilin-1 or their respective isotype controls (n=6-10). Collagen content was determined by trichrome staining and hydroxyproline assay. Gene expression was determined by RT-qPCR and obtained from GEO-NCBI expression arrays, while protein expression by immunohistochemistry, immunoblotting and flow cytometry.</p><p><strong>Results: </strong>Circulating Sema4A was elevated in patients with SSc (p<0.0001), while Sema4A receptors were elevated in SSc skin and lung (p ranged from <0.05 to 0.0001). Anti-Sema4A administration significantly reduced skin and lung collagen content in bleomycin-treated mice (p<0.01), as well as the expression of extracellular matrix components, fibrotic and inflammatory mediators, and immune cell infiltration. In the 3D models, SSc serum and SSc PBMCs induced cell contraction, which was drastically abrogated by blocking Sema4A (p<0.01). This effect was associated with reduced expression of fibrotic mediators and attenuated mTORC1 pathway activation.</p><p><strong>Conclusions: </strong>We confirmed the pro-fibrotic and pro-inflammatory role of Sema4A, postulating Sema4A neutralization as a novel approach for the treatment of SSc.</p>","PeriodicalId":129,"journal":{"name":"Arthritis & Rheumatology","volume":" ","pages":""},"PeriodicalIF":9.9,"publicationDate":"2026-10-20","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149226801","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Christopher T Ritchlin, Philip J Mease, Laura C Coates, Alexa P Kollmeier, Bei Zhou, Yusang Jiang, Karen Bensley, Koeun Im, Rattandeep Batra, Karissa Lozenski, Soumya D Chakravarty, Proton Rahman, Désirée van der Heijde
{"title":"Sustained Inhibition of Structural Damage Progression and Improvements in Disease Activity With Guselkumab in Biologic-Naïve Participants with Active and Erosive Psoriatic Arthritis: Results Through Week 48 of the Phase 3b Randomized, Double-Blind, Placebo-Controlled APEX Study.","authors":"Christopher T Ritchlin, Philip J Mease, Laura C Coates, Alexa P Kollmeier, Bei Zhou, Yusang Jiang, Karen Bensley, Koeun Im, Rattandeep Batra, Karissa Lozenski, Soumya D Chakravarty, Proton Rahman, Désirée van der Heijde","doi":"10.1002/art.70380","DOIUrl":"https://doi.org/10.1002/art.70380","url":null,"abstract":"<p><strong>Objective: </strong>In APEX, guselkumab, which binds to the IL-23p19 subunit and CD64 on IL-23-producing cells, demonstrated significant joint efficacy and inhibition of structural damage progression in participants with active and erosive PsA through Week (W)24; W48 findings are reported herein.</p><p><strong>Methods: </strong>The APEX modified full analysis set included 1020 biologic-naïve adults with active PsA (≥3 tender joints; ≥3 swollen joints; CRP ≥0.3mg/dL; ≥2 erosive joints) randomized to guselkumab every (Q)4W (N=273), guselkumab at W0,4 then Q8W (N=371), or placebo followed by guselkumab Q4W beginning at W24 (N=376). Outcomes through W48 included ACR20/50/70 response rates (using multiple/nonresponder imputation); least squares mean (LSM) change in PsA-modified van der Heijde-Sharp score (vdH-S); achievement of clinically meaningful improvement (CMI; ≥0.35-point) in HAQ-DI, ≥90% improvement in Psoriasis Area and Severity Index (PASI90), and minimal disease activity (MDA).</p><p><strong>Results: </strong>Through W48, 93% (950/1020) of participants completed study intervention. Guselkumab Q4W and Q8W through W48 demonstrated durable ACR20/50/70 response rates (71-74%/51-56%/31-35%), and low rates of structural damage progression (vdH-S LSM change: 0.60-0.78); 60-64% of participants reported HAQ-DI CMI, 74-80% achieved PASI90, 36-41% achieved MDA. Following transition to guselkumab, structural damage progression among placebo-randomized participants diminished (vdH-S LSM change W0-24: 0.96; W24-48: 0.41) and clinical response rates increased through W48. Adverse event rates were consistent with placebo and guselkumab through W24 and stable through W48 of guselkumab.</p><p><strong>Conclusion: </strong>APEX W48 findings further support guselkumab use for durable and comprehensive treatment of diverse PsA manifestations. Inhibition of cumulative joint damage with guselkumab may optimize outcomes.</p>","PeriodicalId":129,"journal":{"name":"Arthritis & Rheumatology","volume":" ","pages":""},"PeriodicalIF":9.9,"publicationDate":"2026-10-20","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149226870","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Hilde Jenssen Bjørkekjær, Cosimo Bruni, Kaspar Broch, Cathrine Brunborg, Patricia E Carreira, Paolo Airò, Carmen Pilar Simeón-Aznar, Marie-Elise Truchetet, Alessandro Giollo, Alexandra Balbir-Gurman, Mickael Martin, Christopher P Denton, Armando Gabrielli, Francesco Del Galdo, Madelon C Vonk, Håvard Fretheim, Helle Bitter, Øyvind Midtvedt, Arne K Andreassen, Sverre Høie, Yoshiya Tanaka, Gabriela Riemekasten, Ulf Müller-Ladner, Marco Matucci-Cerinic, Ivan Castellví, Elise Siegert, Eric Hachulla, Øyvind Molberg, Oliver Distler, Anna-Maria Hoffmann-Vold
{"title":"Initial Treatment Strategies and Outcomes Across Hemodynamic Thresholds and Risk Stratification in Incident Systemic Sclerosis-Associated Pulmonary Arterial Hypertension: A EUSTAR Analysis.","authors":"Hilde Jenssen Bjørkekjær, Cosimo Bruni, Kaspar Broch, Cathrine Brunborg, Patricia E Carreira, Paolo Airò, Carmen Pilar Simeón-Aznar, Marie-Elise Truchetet, Alessandro Giollo, Alexandra Balbir-Gurman, Mickael Martin, Christopher P Denton, Armando Gabrielli, Francesco Del Galdo, Madelon C Vonk, Håvard Fretheim, Helle Bitter, Øyvind Midtvedt, Arne K Andreassen, Sverre Høie, Yoshiya Tanaka, Gabriela Riemekasten, Ulf Müller-Ladner, Marco Matucci-Cerinic, Ivan Castellví, Elise Siegert, Eric Hachulla, Øyvind Molberg, Oliver Distler, Anna-Maria Hoffmann-Vold","doi":"10.1002/art.70372","DOIUrl":"10.1002/art.70372","url":null,"abstract":"<p><strong>Objective: </strong>Real-world initial treatment strategies in systemic sclerosis-associated pulmonary arterial hypertension (SSc-PAH) remain incompletely described. We aimed to characterize these strategies across hemodynamic thresholds and risk strata and evaluate outcome associations.</p><p><strong>Methods: </strong>We analyzed treatment-naive patients with SSc-PAH from the European Scleroderma Trials and Research (EUSTAR) database (2000-2021) who fulfilled the 2022 hemodynamic definition. Initial therapy comprised treatment initiated within four months of right heart catheterization. As-treated (AT) analyses were primary and intention-to-treat (ITT) analyses supportive. Outcomes were all-cause mortality and 36-month PAH progression.</p><p><strong>Results: </strong>Among 301 patients, 198 (66%) initiated therapy and 170 maintained therapy for at least three months. Therapy was initiated in 31% with milder hemodynamic impairment (mean pulmonary arterial pressure 21-24 mm Hg and/or pulmonary vascular resistance 2-3 Wood units) versus 79% fulfilling the previous hemodynamic definition; combination therapy increased from 14% to 67% across low- to high-risk strata. Over a median 3.9 years, 125 patients (42%) died and 85 of 227 (37%) progressed. Adjusted ITT analyses showed no association with either outcome, whereas adjusted AT analyses showed lower mortality risk with sustained monotherapy and combination therapy (hazard ratio [HR] 0.50, 95% confidence interval [CI] 0.27-0.92, and HR 0.40, 95% CI 0.18-0.88, respectively) and lower PAH progression risk with sustained initial therapy (HR 0.37, 95% CI 0.18-0.76). In the milder hemodynamic subgroup, the mortality estimate was directionally consistent but imprecise.</p><p><strong>Conclusion: </strong>Initial treatment strategies reflected hemodynamic severity and baseline risk, whereas variation suggested potential implementation gaps. Sustained initial therapy was associated with lower risks of mortality and PAH progression. Contrasting ITT and AT estimates highlight challenges in observational treatment-outcome comparisons. Findings in the milder hemodynamic subgroup support dedicated prospective studies.</p>","PeriodicalId":129,"journal":{"name":"Arthritis & Rheumatology","volume":" ","pages":""},"PeriodicalIF":9.9,"publicationDate":"2026-10-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149178158","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Namrata Singh, A Jerrod Anzalone, Holland Stevenson, Londyn Robinson, Lesley E Jackson, Sandra E Safo, Zachary Butzin-Dozier, Kaleb Michaud, Maria I Danila, Jasvinder A Singh, Rena C Patel
{"title":"Higher risk of Long COVID among patients with autoimmune rheumatic diseases and immunomodulatory therapy: a retrospective cohort analysis of national US data.","authors":"Namrata Singh, A Jerrod Anzalone, Holland Stevenson, Londyn Robinson, Lesley E Jackson, Sandra E Safo, Zachary Butzin-Dozier, Kaleb Michaud, Maria I Danila, Jasvinder A Singh, Rena C Patel","doi":"10.1002/art.70361","DOIUrl":"https://doi.org/10.1002/art.70361","url":null,"abstract":"<p><strong>Background: </strong>Little is known about the prevalence of and factors associated with Long COVID in patients with autoimmune rheumatic diseases (AIRDs).</p><p><strong>Methods: </strong>We conducted a retrospective cohort study using data from the National Clinical Cohort Collaborative (N3C). We included adults with a first documented SARS-CoV-2 infection between September 2021 and December 2023, with follow-up through December 2024. Long COVID was defined as ICD-10-CM code U09.9 or a Long COVID clinic visit occurring 28 to 365 days after first infection. We compared patients with AIRD with matched non-AIRD controls using 1:1 nearest-neighbor propensity score matching on age with exact matching on sex, race/ethnicity, SARS-CoV-2 variant-dominant period, and data-contributing organization. We estimated hazard ratios using multivariable Cox regression models. Among people with AIRD, we assessed risk by AIRD type and medication exposure before acute COVID-19.</p><p><strong>Results: </strong>In the matched cohort of 187,106 patients, Long COVID occurred in 2.8% of AIRD patients and 1.5% among non-AIRD patients. In multivariable analyses, AIRD was associated with an increased risk of Long COVID compared with non-AIRD patients (aHR 1.56, 95% CI 1.45-1.67). Among patients with AIRD, higher acute COVID-19 severity, pulmonary disease, obesity, and exposure to rituximab or glucocorticoids were associated with an increased risk of Long COVID. Sjögren's syndrome was associated with a higher risk of Long COVID.</p><p><strong>Conclusion: </strong>The higher risk of developing Long COVID among AIRD patients compared with those without AIRD underscores the need to identify potential risk factors for Long COVID in this population to minimize its long-term effects.</p>","PeriodicalId":129,"journal":{"name":"Arthritis & Rheumatology","volume":" ","pages":""},"PeriodicalIF":9.9,"publicationDate":"2026-10-14","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149178160","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
{"title":"EXPRESSION OF CONCERN: Induction of Scleroderma Fibrosis in Skin-humanized Mice by Administration of Anti-platelet-derived Growth Factor Receptor Agonistic Autoantibodies.","authors":"","doi":"10.1002/art.70365","DOIUrl":"https://doi.org/10.1002/art.70365","url":null,"abstract":"<p><strong>Expression of concern: </strong>M. M. Luchetti, G. Moroncini, M. Jose Escamez, S. Svegliati Baroni, T. Spadoni, A. Grieco, C. Paolini, A. Funaro, E. V. Avvedimento, F. Larcher, M. Del Rio, and A. Gabrielli, \"Induction of Scleroderma Fibrosis in Skin-humanized Mice by Administration of Anti-platelet-derived Growth Factor Receptor Agonistic Autoantibodies,\" Arthritis & Rheumatology 68, no. 9 (2016): 2263-2273, https://doi.org/10.1002/art.39728. This Expression of Concern is for the above article, published online on 25 April 2016 in Wiley Online Library (wileyonlinelibrary.com), and has been issued by agreement between the journal Editor-in-Chief, S. Louis Bridges, Jr.; the American College of Rheumatology; and Wiley Periodicals LLC. Concerns were raised by a third party on PubPeer [1] regarding a high level of similarity between the beta-actin bands in Figures 1C and 2B. Additional investigation by the publisher also found that there was evidence of splicing in the PDGFR-alpha band in Figure 3B. The authors responded to an inquiry by the publisher and shared original data. However, original data were not available for the bands originally published in Figure 3B, and the authors supplied data from replicate experiments performed during the same period of the original experiments. A review of these data found that not all of the data could be verified. Therefore, this Expression of Concern has been agreed to in order to inform and alert readers as to the results of this investigation. The authors have been informed of the Expression of Concern.</p><p><strong>Reference: </strong>1. Psychotria siamica. Comments on \"Induction of Scleroderma Fibrosis in Skin-Humanized Mice by Administration of Anti-Platelet-Derived Growth Factor Receptor Agonistic Autoantibodies,\" PubPeer, November 2025. https://pubpeer.com/publications/33B47982F70FD05FFA5D7CE38D417A.</p>","PeriodicalId":129,"journal":{"name":"Arthritis & Rheumatology","volume":" ","pages":""},"PeriodicalIF":9.9,"publicationDate":"2026-10-12","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149163316","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
{"title":"Training Opportunities Within the National Institute of Arthritis and Musculoskeletal and Skin Diseases","authors":"Janelle Hauserman, Isaah Vincent","doi":"10.1002/art.70347","DOIUrl":"https://doi.org/10.1002/art.70347","url":null,"abstract":"","PeriodicalId":129,"journal":{"name":"Arthritis & Rheumatology","volume":"40 1","pages":""},"PeriodicalIF":13.3,"publicationDate":"2026-10-09","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149130525","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
{"title":"Tph and Tfh cells as biomarkers and targets in rheumatic diseases","authors":"Abigail E. Schiff, Deepak A. Rao","doi":"10.1002/art.70362","DOIUrl":"https://doi.org/10.1002/art.70362","url":null,"abstract":"The role of B cell‐helper T cells, including T follicular helper cells (Tfh), T peripheral helper cells (Tph), and others, in autoimmune rheumatic diseases is reviewed, focusing on clinical applications. A case is presented where the presence of B helper T cells could help decide the next medication to use in a patient with rheumatoid arthritis refractory to TNF inhibitors. The review covers topics including the biology of B cell and T cell interactions, the origin and function of B cell‐helper T cells, disease associations, B cell‐helper T cells as a marker of disease phenotype and treatment response, and therapeutic approaches. B cell‐helper T cells are a subset of CD4+ T cells that are specialized to aid in B cell development and affinity maturation. B cell‐helper T cells, including Tfh and Tph cells, are positively correlated with increased disease activity and lymphoid aggregate‐associated phenotypes in multiple autoantibody‐associated immune conditions. Higher numbers of circulating Tfh and Tph cells are also associated with greater likelihood of response to certain biologics in rheumatoid arthritis. In the future, Tfh and Tph cell levels may be used as both biomarkers of disease activity and targets to treat multiple autoantibody‐associated rheumatic diseases, leading to a new era of personalized medicine.","PeriodicalId":129,"journal":{"name":"Arthritis & Rheumatology","volume":"12 1","pages":""},"PeriodicalIF":13.3,"publicationDate":"2026-10-09","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149130522","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Dong‐Jin Park,Sung‐Eun Choi,Ji‐Hyoun Kang,Jung‐Yoon Choe,Hye‐Soon Lee,So‐Young Bang,Yun‐Hong Cheon,Sang‐Il Lee,Mingyo Kim,Yoon‐Kyoung Sung,Soo‐Kyung Cho,Jae Hyun Jung,Sung Hae Chang,Sung Won Lee,Yeon‐Ah Lee,Seung‐Geun Lee,Hyun‐Sook Kim,Seung‐Ki Kwok,Seung‐Cheol Shim,Shin‐Seok Lee
{"title":"Outcomes of Tapering Biologic and Targeted Synthetic DMARDs in Rheumatoid Arthritis: A Multicenter Randomized Non‐Inferiority Trial","authors":"Dong‐Jin Park,Sung‐Eun Choi,Ji‐Hyoun Kang,Jung‐Yoon Choe,Hye‐Soon Lee,So‐Young Bang,Yun‐Hong Cheon,Sang‐Il Lee,Mingyo Kim,Yoon‐Kyoung Sung,Soo‐Kyung Cho,Jae Hyun Jung,Sung Hae Chang,Sung Won Lee,Yeon‐Ah Lee,Seung‐Geun Lee,Hyun‐Sook Kim,Seung‐Ki Kwok,Seung‐Cheol Shim,Shin‐Seok Lee","doi":"10.1002/art.70363","DOIUrl":"https://doi.org/10.1002/art.70363","url":null,"abstract":"Objective Evidence supporting tapering of biologic or targeted synthetic disease‐modifying antirheumatic drugs (b/tsDMARDs) in rheumatoid arthritis (RA) patients with sustained low disease activity (LDA) remains limited. We evaluated the efficacy and safety of a structured b/tsDMARD tapering strategy in patients with RA who had achieved sustained LDA. Methods In this 24‐week, multicenter, randomized, open‐label, non‐inferiority trial, patients with RA receiving stable‐dose b/tsDMARDs and maintaining DAS28‐ESR‐defined LDA for at least 6 months were randomized to either stepwise dose tapering or dose continuation. The primary endpoint was maintenance of DAS28‐ESR LDA at week 24. The non‐inferiority margin was prespecified as ‐10%. Secondary endpoints included disease activity measures, remission rates, patient‐reported outcomes, quality of life, and adverse events. Results A total of 348 patients were randomized to the continuation group (n=177) or tapering group (n=171). In the per‐protocol population, LDA was maintained in 89.6% and 88.2% of patients, respectively, with a risk difference of ‐1.43% (95% CI ‐8.09 to 5.23), meeting the prespecified criterion for non‐inferiority. Similar findings were observed in the full analysis set. Most patients experiencing disease worsening regained low disease activity after protocol‐guided treatment re‐escalation during follow‐up without permanent treatment discontinuation. Most secondary outcomes were comparable between groups, although some disease activity measures favored continuation, including DAS28‐CRP at week 12 and DAS28‐ESR and SDAI at week 24. Adverse events were uncommon in both groups. Conclusion In RA patients with sustained LDA, structured b/tsDMARD tapering was non‐inferior to treatment continuation for maintaining disease control over 24 weeks.","PeriodicalId":129,"journal":{"name":"Arthritis & Rheumatology","volume":"1 1","pages":""},"PeriodicalIF":13.3,"publicationDate":"2026-10-06","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149089218","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}